Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chuanzhitongluojiaonang is a Traditional Chinese Medicine (TCM) hospital preparation developed by The Second Affiliated Hospital of Chongqing Medical University. It is primarily investigated for the treatment of acute ischemic stroke (AIS). The formulation typically contains extracts from *Chuanxiong* (Ligusticum wallichii) and *Shuizhi* (Leech/Hirudo). These components are traditionally used to promote blood circulation and resolve blood stasis. Pharmacologically, ingredients like hirudin from leeches act as potent thrombin inhibitors, while tetramethylpyrazine from Chuanxiong provides vasodilatory and anti-platelet effects. The drug is currently being evaluated in multicenter clinical trials to assess its efficacy and safety in improving neurological outcomes in stroke patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on chuanzhitongluojiaonang (The 2nd Affiliated Hospital of Chongqing Medical University).